Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin ... to invalidate five patents for a pen-type injection device that allows a user to set and ...

The new insulin delivery device was launched today ... of loading or changing insulin cartridges burdensome and even difficult," he said. The Lantus ClikSTAR pen, designed in partnership with ...

Mylan CEO Heather Bresch commented, "Today's decision by the U.S. Patent and Trademark Appeal Board invalidating Sanofi's Lantus device patents ... disposable injection pen (Lantus SoloSTAR®).

Biocon Biologics has announced that the US Court of Appeals for the Federal Circuit (USCAFC) has upheld the US Patent and Trademark Appeal Board’s decisions for unpatentability of five device ...

* MYLAN - PTAB FOUND THREE CLAIMS OF 9,604,008 PATENT UNPATENTABLE, AND TWO CLAIMS TO BE PATENTABLE Source text for Eikon: Further company coverage: Healthcare & Pharmaceuticalscategory US FDA ...

Mylan CEO Heather Bresch commented, "Today's decision by the U.S. Patent and Trademark Appeal Board invalidating Sanofi's Lantus device patents is another significant ... and as a disposable injection ...

MYLAN - PTAB RULED IN FAVOR OF CO IN IPR PROCEEDINGS FINDING ALL CHALLENGED CLAIMS OF SANOFI'S LANTUS SOLOSTAR DEVICE PATENTS * MYLAN - PTAB FOUND THREE CLAIMS OF 9,604,008 PATENT UNPATENTABLE ...